• Treace Medical Concepts CEO John T. Treace bought 50,000 common shares at a weighted average price of $3.56.
• Directly held stake rose to 7,323,833 shares following the purchase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Treace Medical Concepts Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-251587), on June 01, 2026, and is solely responsible for the information contained therein.